The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. This invention relates generally to the prevention and treatment of diseases and conditions mediated by the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not limited to the relief joint discomfort and pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse.

Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent

The present invention provides a novel method for simultaneously inhibiting the cyclooxygenase COX-2 and 5-lipoxygenase (5-LO) enzymes. The method for the simultaneous dual inhibition of COX-2 and 5-LO is comprised of administering a composition containing an individual and/or a mixture of multiple flavans isolated from a single plant or multiple plants in the Acacia genus of plants to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 and 5-LO mediated diseases and conditions. The method for preventing and treating COX-2 and 5-LO mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising an individual and/or a mixture of multiple flavans isolated from a single plant or multiple plants in the Acacia genus of plants and a pharmaceutically acceptable carrier. The present invention includes a method for isolating and purifying a composition of flavans having dual specificity for COX-2 and 5-LO from the Acacia genus of plants.

Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia

The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds --Free-B-Ring flavonoids and flavans-- for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in normal, aged and damaged dermal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the skin mediated by cyclooxygenase (COX) and lipoxygenase (LOX). The method for preventing and treating COX-2 and 5-LO mediated diseases and conditions of the skin is comprised of topically administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of COX and LOX mediated diseases and conditions, including but not limited to sun burns, thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitilago, systemic lupus erythromatosus, psoriasis, carcinoma, melanoma, as well as other mammal skin cancers, skin damage resulting from exposure to ultraviolet (UV) radiation, chemicals, heat, wind and dry environments, wrinkles, saggy skin, lines and dark circles around the eyes, dermatitis and other allergy related conditions of the skin. Use of the composition described herein also affords the benefit of smooth and youthful skin with improved elasticity, reduced and delayed aging, enhanced youthful appearance and texture, and increased flexibility, firmness, smoothness and suppleness.

Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care

PROBLEM TO BE SOLVED: To provide a skin care preparation which is compatible with the skin and can exhibit a high skin moisture-retaining effect, a high skin-beautifying effect and a high skin roughness-improving effect. SOLUTION: This skin care preparation contains an extract of Chamaenerion angustifolium (L.) Scop. or Epilobium angustifolium L., and an extract of one or more plants selected from Calendula officinalis L., Petroselinum crispum (Mill.), Melissa officinalis L, Tussilago farfara L., Althaea officinalis L., Aesculus turbinata Blume or Aesculus hippocastanum L., Daucus carota L., Potentilla tormentilla, Hypericum erectum Thunb. or Hypericum perforatum L., Salvia officinalis L., Cucumis sativus L., Foeniculum vulgare Miller, Sambucus nigra L., Arnica montana L., Ononis spinosa L., Geranium nepalense Sweet. var. thunbergii (Sieb. et Zucc.) Kudo, Carthamas tinctorius L., Ophelia japonica (Schult.) Griseb., Saponaria officinalis L., Apium graveloens L. var. dulce (Mill.) Pers., Melilotuis officinalis L., Luffa cylindrica (L.) Roem, Saxifraga stolonifera Meerb., Paeonia suffruticosa Andr., Malva sylvestris L., Hamamelis virginiana L., Ziziphus jujuba Mill., Coptis japonica (Thunb.) Makino, Paeonia lactiflora Pall., Angelica acutiloba (Sieb. et Zucc.) Kitagawa, Cnidium officinale Malino, Asiarum sieboldi (miq.) F. Maekawa, Scutellaria baicalensis Georgi, Uncaria gambir (Hunt) Rocb., Poria cocos (Fr.) Wolf, Rehmannia glutinosa (Gaertn.) Libosch., Cinnamomi cassia Presl., Phellodendron amurense Pupr., Phellodendron amurense Pupr., Curcuma domestica Valet., Syzygium aromaticum (L.) Merril et Perry, Artemisia princeps Pamp., Zingiber officinale Rosc., Ganoderma lucidum (Leyss. ex Fr.) Karst, Coix lachryma-jobi L., Prunus armeniaca L., Prunus persica (L.) Batsch, Citrus junos Sieb. et Tanaka, Pueraria lobata (Willd.) Ohwi, Citrus unshiu Marcovitch, and Cuminum cyminum L., and fungi. COPYRIGHT: (C)2004,JPO

Skin care preparation

High-molecular compounds comprising repeating units represented by the general formula (1) or (2) and having number-average molecular weights of 103 to 108 in terms of polystyrene: (1) [wherein Ar1 and Ar2 are each independently a trivalent aromatic hydrocarbon group or a trivalent heterocyclic group; and X1 and X2 are each independently O, S, C(=O), S(=O), SO2, C(R1)(R2), Si(R3)(R4), N(R5), B(R6), P(R 7), or P(=O)(R8), with the provisos that X1 and X2 must not be the same and that X1and Ar2 are bonded respectively to the adjacent carbon atoms constituting the aromatic ring of Ar1, and X2 and Ar1 are bonded respectively to the adjacent carbon atoms constituting the aromatic ring of Ar2] (2) [wherein Ar3 and Ar4 are each independently a trivalent aromatic hydrocarbon group or a trivalent heterocyclic group; and X3 and X4 are each independently N, B, P, C(R9), or Si(R10), with the provisos that X3 and X4 must not be the same and that X3 and Ar4 are bonded respectively to the adjacent carbon atoms constituting the aromatic ring of Ar3, and X 4 and Ar3 are bonded respectively to the adjacent carbon atoms constituting the aromatic ring of Ar4].

High-molecular compounds and polymer light emitting devices made by using the same

PROBLEM TO BE SOLVED: To obtain a hyaluronic acid decomposition inhibiting agent to directly act on the cell originated from human connective tissue and inhibit the decomposition of hyaluronic acid, an agent for the treatment of hyaluronic acid decomposition disease containing the hyaluronic acid decomposition inhibitor, and a cosmetic effective for preventing the aging of skin caused by the lowering of the amount of hyaluronic acid. SOLUTION: This hyaluronic acid decomposition inhibitor contains the extraction liquid or extracted component of one or more herb drugs or plants selected from arnica (flower and root of Arnica montana, Ikarisou (whole grass of Epimedium grandiflorum), eleutherocock (root of Eleutherococcus senticosus), Ouhi (back of Prunus jamasakura), Onji (root of Polygala tenuifolia), Keihi (bark of Cinnamomum cassia), Gokahi (root of Acanthopanax gracilistylus), peppermint, senega (root of Polygala senega), Tachijakousou (ground part of Thymus vulgaris), Asen-yaku (Acacia catechu), Choji (flower bud of Syzigium aromaticum) and Dokudami (whole grass of Houttyunia cordata). The agent for the treatment of hyaluronic acid decomposition disease contains the hyaluronic acid decomposition inhibitor. The cosmetic contains the hyaluronic acid decomposition inhibitor containing one or two herb drugs selected from Muiapuama (root of Liriosma ovata) and Mokkin (flower, bark, etc., of Hibiscus syriacus).

Hyaluronic acid decomposition inhibitor, agent for treatment of hyaluronic acid abnormal decomposition disease and cosmetic

PROBLEM TO BE SOLVED: To obtain the subject agent which can increase the hyaluronic acid content of the horny layer to optimize the water environment and hardness of the horny layer, allows to expect an effect for preventing rough skins and wrinkles, is stable in preparations, and is useful for skin cosmetics, by including N-acetylglucosamine. SOLUTION: This agent for increasing the hyaluronic acid content of a horny layer comprises N-acetylglucosamine. The agent is preferably added to a skin cosmetic preferably in an amount of 0.001 to 10%, especially preferably 0.01 to 5%, based on the total amount of the cosmetic composition. The agent may preferably further be compounded with a polyhydric alcohol such as 1,3-butylene glycol, a vitamin derivative such as an ascorbic acid phosphoric acid ester salt, an anionic surfactant such as N-stearoyl-L-glutamic acid salt, and so on.

Agent for increasing hyaluronic acid content of horny layer

PROBLEM TO BE SOLVED: To provide a composition for external skin preparation which promotes the production of epidermal hyaluronic acid and can keep the tension and moisture of the skin. SOLUTION: The composition for external skin preparation characteristically contains N-acetylglucosmine and retinoids.

Composition for external skin preparation

PURPOSE: To obtain a hyarulonic acid production promoter containing, as active ingredient, yeast extract, capable of promoting the hyarulonic acid productivity in human skin fibroblast, thus useful for preventing skin aging and treating such diseases as to involve the abnormal decomposition of hyarulonic acid, and safe to the human body. CONSTITUTION: A mixture comprising cetanol, lipophilic monostearic acid glycerin-polyoxyethylene cetyl ether, liquid paraffin, methylpolysiloxane, etc., is first prepared by homogeneously mixing these components at 80°C, and butyl p-oxybenzoate is added to and dissolved in the mixture. Separately, a second mixture comprising sodium N-stearoyl-L-glutamate, dipropylene glycol and water is prepared by homogeneously mixing these components at 80°C, and a yeast extract is added to and dissolved in this mixture. Subsequently, the resultant two solutions are mutually mixed and then cooled to 30°C under through agitation, thus obtaining the objective promoter having the above- mentioned advantages. COPYRIGHT: (C)1996,JPO

Hyarulonic acid production promoter

PROBLEM TO BE SOLVED: To obtain an inhibitor for decomposition of hyaluronic acid, acting on a cell which exists in human binding tissue and inhibiting decomposition of hyaluronic acid and useful as an agent for improving and treating diseases causing abnormal decomposition of hyaluronic acid such as rheumatism, osteoarthritis and malignant tumor by including heparin. SOLUTION: This inhibitor contains heparin and/or its salt extracted according to ordinary method from intestine or the like of pig or the like, preferably in an amount of 0.001-5 g based on 100 g total amount of medicine. Daily doses of the compound is preferably 1-10 g as total amount of heparin and its salt in the case of oral administration and preferably 0.1-5 g in the case of parenteral administration. The medicine is useful as an agent for improving and treating diseases causing abnormal decomposition of hyaluronic acid, e.g. hepatitis, gingivitis and fibrosis.

Inhibitor for decomposition of hyaluronic acid, agent for improving and treating disease causing abnormal decomposition of hyaluronic acid and agent for preventing gingivitis and agent for preventing dry skin or rough skin

哲也佐用

Papers

Hyaluronic acid decomposition inhibitor, agent for treatment of hyaluronic acid abnormal decomposition disease and cosmetic

Agent for increasing hyaluronic acid content of horny layer

Composition for external skin preparation

Hyarulonic acid production promoter

Inhibitor for decomposition of hyaluronic acid, agent for improving and treating disease causing abnormal decomposition of hyaluronic acid and agent for preventing gingivitis and agent for preventing dry skin or rough skin

哲也 佐用

Papers

Hyaluronic acid decomposition inhibitor, agent for treatment of hyaluronic acid abnormal decomposition disease and cosmetic

Agent for increasing hyaluronic acid content of horny layer

Composition for external skin preparation

Hyarulonic acid production promoter

Inhibitor for decomposition of hyaluronic acid, agent for improving and treating disease causing abnormal decomposition of hyaluronic acid and agent for preventing gingivitis and agent for preventing dry skin or rough skin

哲也佐用